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Abstract
This review was performed to assess the use of optical
coherence tomography in diabetic retinopathy and
maculopathy and its application in the diagnosis and
management of these conditions. A comprehensive
literature search on MEDLINE was performed for
studies published until 2013 with key words 'diabetes
mellitus', 'optical coherence tomography', 'diabetic
retinopathy', 'diabetic maculopathy', 'intersessional
repeatability', 'diurnal variation' , 'fundus autofluo-
rescence' and 'treatment'. Search results were limited
to studies published in English and in human subjects
only. The Early Treatment Diabetic Retinopathy Study
established the current standard of care for diabetic
retinopathy and maculopathy with the diagnosis based
on slit-lamp biomicroscopy, indirect ophthalmoscopy,
and fluorescein angiography. There has been a recent
4
shift to the use of optical coherence tomography in
the qualitative and quantitative assessment of such
diseases. Furthermore, the advancement of optical
coherence tomography from time-domain to spectral-
domain technology allows us to visualize pathological
changes of diabetic maculopathy in details in different
retinal layers. Such observed changes have been used
to establish new classifications of diabetic maculo-
pathy. The high sensitivity and quantitative nature
of optical coherence tomography make it a highly
popular modality used extensively to monitor disease
progression and efficacy of new treatment modalities.
Optical coherence tomography plays a crucial role in
the modern clinical management of diabetic retino-
pathy and maculopathy. Its use has revolutionized the
understanding and management of these eye diseases.
Key words: Diabetic retinopathy; Macular degeneration;
Tomography,opticalcoherence
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Introduction
The current standard of care for diabetic retinopathy was
established by the Early Treatment Diabetic Retinopathy
Study (ETDRS) conducted in the late 1980s.1,2Diagnosis
was mainly based on slit-lamp biomicroscopy, indirect
ophthalmoscopy, and fundus fluorescein angiography
(FFA)? However, these clinical findings are subjective and
the assessments are difficult to quantify objectively. Since
the introduction of optical coherence tomography (aCT)
in 1995,4.7 it has quickly been incorporated into the daily
management of retinal diseases.v' Recent advances in aC'P
technology improved our understanding of the anatomy
of the retina in diabetic retinopathy and pathogenesis of
the condition, and also revolutionized the diagnosis and
management of this blinding disease,"
In a recent randomized controlled trial conducted by the
Diabetic Retinopathy Clinical Research Network (DRCR.
net), aCT measurements of macular thickness were adopted
as primary monitoring parameters in the management of
patients with diabetic maculopathy.' This established the
vital role of aCT in the modern management of diabetic
retinopathy. This review provides up-to-date information
regarding the use of aCT in diabetic retinopathy.
Methods
A comprehensive literature search on MEDLINE was
performed for studies published until 2013 with key words
'diabetes rne llitus ", 'optical coherence tomography',
'diabetic retinopathy', 'diabetic maculopathy', 'intersessional
repeatability", 'diurnal variation', 'fundus autofluorescence'
and 'treatment' . Search results were limited to studies
published in English and in human subjects only. Selected
papers were then reviewed thoroughly and evidence was
summarized.
What is optical coherence tomography?
aCT is a non-contact and non-invasive imaging modality
used to perform high-resolution, cross-sectional imaging.
Images obtained by aCT are finer than those obtained by
conventional imaging technologies such as ultrasound,
magnetic resonance imaging or computed tomography. It
allows both qualitative assessment of the retinal contour and
quantitative measurement of retinal thickness.
Principles of optical coherence tomography
aCT utilizes interferometry to acquire high-resolution in-
vivo retinal images. Infrared light is projected onto the retina
(A-scans), and reflectance data from backscattered light are
interpreted. This is similar to the principle of ultrasonography
except that aCT utilizes light wave (with much shorter
wavelength of 700-800 nanometers) resulting in a much
higher resolution. The retinal nerve fiber layer thickness
can be calculated using automated segmentation algorithm.
A cross-sectional image of the retina can be reconstructed
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by combining data from a series of side-by-side Avscans.t-'
The widely available Stratus aCT, a third-generation aCT
instrument produced by Carl Zeiss Meditec (Dublin [CA],
USA), utilizes 'Time' domain technology, where data from
a moving reference mirror within the machine are compared
with the interference pattern generated by echo time delays
of backscattered light from the subject's retina.P'? By this
method, the Stratus aCT gives an axial resolution of 8 to 10
microns and a scan speed of 400 A-scans per second. Using
different scanning protocols, images focusing on the macula,
optic disc and areas of particular interest can be interpreted.
In-vivo pre-retinal, intra-retinal and sub-retinal anatomy and
pathology can be delineated to aid clinical decisions."
Recently, several manufacturers have developed a
new generation of aCT utilizing the' Spectral' domain
technology, which is also known as the 'Fourier domain'
aCT. Examples include Cirrus Spectral-domain aCT (Carl
Zeiss Meditec; Dublin [CA], USA), Nidek RS-3000 aCT
(Nidek Co. Ltd., Garnagori, Aichi, Japan), Spectralis aCT
(Heidelberg Engineering, Heidelberg, Germany) and Topcon
3D aCT-2000 (Topcon Corporation, Japan). The Spectral-
domain technology does not require a reference mirror
and does not measure reflectivity of each A-scan at a time.
Instead, the spectrometer senses the relativity of multiple
Figure 1. Optical coherence tomography scan through a normal
central fovea.
(a) Image acquired using time-domain OCT (Stratus OCT, Carl
Zeiss Meditec, USA); (b) Image acquired in same patient using
spectral-domain OCT (Spectralis OCT, Heidelberg Engineering,
USA). Note the higher resolution. Different layers within the retina
can be clearly seen.
Abbreviations: ELM = external limiting membrane; GCL = ganglion
cell layer; 1NL = inner nuclear layer; IPL = inner plexiform layer;
IS/OS = photoreceptor inner segment/outer segment; NFL = nerve
fiber layer; OCT = optical coherence tomography; ONL = outer
nuclear layer; OPL = outer plexiform layer; OST = photoreceptor
outer segment tip; RPE = retinal pigment epithelium.
5
REVIEW ARTICLE
optical frequencies simultaneously from the backscattered
light. Thus, many sample points can be measured at the same
time allowing up to 100 times faster scanning acquisition
speed. This new generation of aCT is able to produce axial
resolution of 5 microns and a scan speed of up to 40,000
A-scans per second. Collected data are calculated using
Fourier transformation. This allows imaging of the retina at
much greater precision.P:" Normal aCT cross-section of
the foveal region is shown in Figure 1. With the improved
technology, a 3-dimensional image of the in-vivo retina can
also be produced.
Advantages of optical coherence
tomography
Quantifying retinal thickness
A major advantage of aCT is its ability to quantify retinal
thickness." The assessment of retinal status by traditional
imaging modalities is subjective and qualitative. In
comparison, retinal thickness measured by aCT can be
quantified in terms of microns, and mapped out according
to the topographic data obtained. Quantification of retinal
thickness is made possible by calculating the distance
between the anterior and posterior highly reflective interfaces
of the retina. The anterior interface (the internal limiting
membrane) is well defined on aCT due to its contrast
with the non-reflective vitreous. The posterior border (the
retinal pigment epithelium) is well defined on aCT as the
first signal posterior to the low-scattered photoreceptor
layer.' Quantification of retinal thickness by aCT provides
more accurate monitoring and documentation of disease
progression than with traditional imaging modalities.
Non-invasiveness and convenience
aCT measurements are taken easily with the patients sitting
and resting their head on the chin-rest of the machine.
Unlike ultrasound biomicroscopy, there is no contact with
the patient's eye, which enhances patient's comfort and
reduces the risk of cross-infection. Unlike FFA, no contrast
is required, which reduces the risk of adverse drug reaction
and anaphylaxis. The newest generations of OC'Is allow
measurements in patients with undilated pupils as small as 3
millimetres," thus, increasing the convenience of use.
Improved sensitivity
aCT is highly sensitive in detecting early changes such
as minimal early macular edema. Hee et aP have shown
that aCT can detect early retinal changes even when slit-
lamp biomicroscopy shows normal findings+' Brown et
al'? have shown that aCT is better in detecting early retinal
edema than biomicroscopy. Serous retinal detachment and
vitreomacular interface (VMI) changes can also be more
easily visualized with aCT than biomicroscopy,"
Correlation with visual acuity
Studies have shown that retinal thickness in diabetic macular
edema (DME) correlates well with visual function.v" In
the prospective study by Alkuraya et al," central macular
thickness was significantly correlated with visual acuity. A
study conducted by DRCR.net showed that every 100 micron
decrease in central foveolar thickness corresponds with
an improvement of visual acuity by 4.4 ETDRS letters."
A recent study showed that an increase in central sub field
thickness in patients with DME corresponds to worsening of
best-corrected visual acuity." Thus, aCT shows advantage
over traditional imaging modalities in prediction of visual
outcome.
Optical coherence tomography findings in
diabetic retinopathy
In the ETDRS, aCT findings were not included because
aCT was not commercially available when the study was
performed (Tables 1 and 2).1.2 Although aCT assessment
Table 1. Classification of diabetic retinopathy accoeding to the Early Treatment Djabetic Retinopathy $tudy.l~ '"
Grade Findings Treatment recommended'
Non-proliferative
MildNPDR Presence of at least I microaneurysm, but not enough to qualify as moderate NPDR DM control
Moderate NPDR Extensive intraretinal hemorrhages and 1or microaneurysms, IRMA, venous beading, DM control
but not to the degree of severe NPDR
Severe NPDR 4-2-1 rule: DM control
· Intraretinal hemorrhage and 1 or microaneurysms in all 4 quadrants; Consider early prophylactic scattered PRP· Venous beading in at least 2 quadrants; where progression is likely· IRMA in at least 1 quadrant
Proliferative
PDR Presence of NVD or NVE DMcontrol
PRP
High-risk PDR Anyone of: DMcontrol
·NVD ~1I4 to 1/3 disc area PRP· Any NVD with VH·NVE ~1/2 disc area with VH
Abbreviations: DM = diabetes mellitus; IRMA = intra-retinal microvascular abnormalities; NPDR = non-proliferative diabetic retinopathy; NVD = neovasculariration at disc;
NVE = neovascularization elsewhere; PDR = proliferative diabetic retinopathy; PRP = panretinal photocoagulation; VH = vitreous hemorrhage .
• According to the recommendation set out in the Early Treatment Diabetic Retinopathy Study.
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Table 2. Classification of macular edema (i.e. CSME) according to the Early Treatment Diabetic Retinopathy Study.t-'
Definition (at least 1 of following) Treatment'
1. Retina! thickening ,,500 urn of the FAZ l. Focal laser to microaneurysms
2. Hard exudates ,,500 Ilffi of the FAZ with associated thickening of the adjacent retina 2. Grid laser to edematous retina within the macular region
3. Retinal thickening ~1 disc area in size sl disc diameter from the center of fovea
Abbreviations: CSME = clinically significant macular edema; FAZ =foveal avascular zone .
• According 10 the recommendation set out in the Early Treatment Diabetic Retinopathy Study.
Table 3. Review of optical coherence tomography classification systems by different authors with details.
Classification Year OCT Grade Features ~
Otani et al" 1999 TD N/A Sponge-like swelling of retina (~250 urn)
Cystoid macular edema
Serous retinal detachment
Hyper-reflective spots (representing intraretinal exudates)
Panozzo et al27 2004 TD Retina! thickness for central zone
Normal 170 ± 20 Ilffi
Borderline 190-230 urn
Edema ,,230 urn
Morphology (E)
El Simple thickening
No clinical visible cystoid spaces
E2 Cystoid thickening (range from a to c). Defined as circular or ovaloid space with no reflectivity. Cyst
has minimal size of horizontal 150 Ilffi and vertical 300 urn
E2a Mild thickening with 2-4 central small cysts. Cyst size: horizontal 150-220 urn, vertical ,,400 urn
E2b Intermediate thickening with petaloid cysts or central big cysts. Cyst size: horizontal ,,300 urn, vertical
,,600 urn.
E2c Severe thickening with coalescence of cyst with retinoschisis appearance
E3 Neuroepithelial detachment. Defined as the presence of subretinal fluid above the hyper-reflecting line
of the pigmented epithelium. Can be isolated or associated with El or E2
Epiretinal traction (T)
Well-defined and continuous hyper-reflective line over inner retinal surface with at least one point of adhesion to retina
TO Absence of epiretinal hyper-reflectivity
T1 Presence of a continuous line without significant retinal distortion
T2 Presence of line with multiple points of adhesion with significant retinal distortion
T3 Anteroposterior traction with 'gull-wings' configuration
Kang et al28 2004 TD Type 1 Thickening of fovea with homogeneous optical reflectivity throughout whole layer of retina
Type 2 Thickening of fovea with markedly decreased optical reflectivity in outer retina
Type 3A Thickening of fovea with subfoveal fluid accumulation and detached retina without foveal traction
Type 3B Thickening of fovea with subfoveal fluid accumulation and detached retina with fovea! traction
Alkura ya et aF' 2005 TD Type 1 Sponge-like retinal swelling
Type 2 Cystoid macular edema
Type 3 Serous retinal detachment
. Type 4 Vitreo-foveal traction
Kimetal'9 2006 TD DRT Diffuse retinal thickening
CME Cystoid macular edema
SRD Serous retinal detachment
PHT,no TRD Posterior hyaloidal traction without traction retinal detachment
PHT+TRD PHTwithTRD
Soliman et a!30 2007 TD Pattern I Angiogram leak without corresponding change in morphology or thickness of retina
Pattern 2 Diffuse or localized thickening of ONUHenle's layer
Pattern 3 Pattern 2 + cystic changes of ONLlHenle's layer
Pattern 4 Pattern 3 + cystic changes of 1NL
Pattern 5 Pattern 4 + serous detachment of neural retina
Abbreviations: 1NL = inner nuclear layer; N/A = not applicable; aCT = optical coherence tomography; ONL = outer nuclear layer; PHI = posterior hyaloidal traction; TD = time-
domain; TRD = traction retinal detachment.
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played a major role in the trial by DRCR.net, a classification
of aCT features of diabetic retinopathy/maculopathy
was not defined." There are a few proposed OC'Ivbased
classification systems but none has been conclusive.18.25.27.29
This is because most were based on small-scale studies and
none has histopathological correlations. Most classifications
were based on the aCT changes observed involving: (1)
the VMI (above the retina), (2) intraretinal changes (within
the retina), and (3) subretinal changes (below the retina). A
review of proposed classification systems is given in Table
3.18.25,27.30
Vitreomacular interface changes
The vitreous has been thought to play an important role in
the pathogenesis of diabetic maculopathy." Vitreomacular
traction (VMT) has been proposed to cause macular edema.
In recent reports, VMI abnormalities such as posterior
hyaloid-retinal adhesion, and epiretinal membrane formation
were found to be highly prevalent in eyes with persistent
diabetic macular edema (PDME).19,31.33 Therefore, in
macular edema cases with traction, vitrectomy to release
a taut adherent posterior hyaloid is the treatment of choice
as traditional laser photocoagulation was found to be
ineffective. However, the diagnosis of VMT can be difficult
without the use of aCT.31 Figure 2 shows some VMI
abnormalities detected by aCT.
Intraretinal changes
DME is postulated to be the result of the breakdown of
blood-retina barrier. Proteins and exudates extravasated from
leaky intraretinal vessels create an osmotic pressure that
leads to the formation of retinal edema and cysts. Soliman
et apo devised a grading system for DME based on aCT
findings and correlated with fundus angiogram findings.
They found that early DME angiographic leakage could
have no morphological change on initial aCT. However,
progression of macular edema corresponds with thickening
in the outer nuclear layer. Further progression with
involvement of the inner nuclear layer is associated with
intraretinal cyst formation. Figures 3a and 3b show some
intraretinal changes observed with aCT.
In a recent study using spectral-domain aCT, Bolz et aP4
observed hyper-reflective foci within the retina that could
not be visualized previously using time-domain technology.
These foci could not be seen on biomicroscopy or fundus
angiogram due to their small size (<30 microns) [Figure
3]. Bolz et aP4 postulated that these foci might represent
extravasated protein due to breakdown of the blood-
retina barrier in diabetic retinopathies. Further studies
were carried out to delineate the nature of these foci and
their correlation with clinical presentation. Although a
standardized grading system is yet to be developed, a wide
Figure 2. Optical coherence tomography (OCT) images of vitreomacular interface abnormalities.
(a)Time-domain image OCT (Stratus OCT, Carl ZeissMeditec, USA)showing posterior hyaloid face partially adherent to the fovea (arrow);
(b) Spectral-domain OCT (Spectralis OCT, Heidelberg Engineering, USA) showing adherent posterior hyaloids at the fovea causing edema
and intraretinal cystic change (arrow); (c) Spectral-domain OCT (Spectralis OCT, Heidelberg Engineering, USA) 3D reconstruction of
the same cut in (b); (d) Spectral-domain OCT (Nidek RS-3000 OCT, Japan) showing very advanced vitreoretinal interface abnormality
with poor clinical response after traditional laser treatment and requiring surgical intervention.
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Figure 3. Optical coherence tomography (OCT) images demonstrating intraretinal, subretinal pathologies and before-and-after treatment
appearances.
OCT images of intraretinal abnormalities: (a) Time-domain OCT (Stratus OCT, Carl Zeiss Meditec, USA) showing disruption of foveal
"contour, edema and intraretinal cystic changes (white arrow); (b) Spectral-domain OCT (Nidek RS-3000 OCT, Japan) showing similar
intraretinal cyst formation in higher resolution (white arrow); hyper-reflective foci within the retina associated with edema (red arrow),
which is not seen in (a).
OCT images of subretinal abnormalities: (c) Time-domain OCT (Stratus OCT, Carl Zeiss Meditec, USA) image showing subretinal serous
macular detachment with overlying retinal edema and cystic changes. (d) Spectral-domain OCT (Spectralis OCT, Heidelberg Engineering,
USA) image showing similar findings with the addition of hyper-reflective foci within the retina.
Time-domain OCT comparison of pre- and post-treatment macula: Time-domain OCT (Stratus OCT, Carl Zeiss Meditec, USA) image
showing the fovea (e) before and (f) 3 months after laser treatment. There is reduction of retinal thickness after successful laser treatment.
variety of morphological changes in diabetic maculopathy
are observed .with OCT, which allows further understanding
of the pathogenesis of DME.
Subretinal changes
Several reports describe the formation of localized
serous retinal detachment in severe cases of diabetic
maculopathy.18.25.27.30 Leaky blood vessels allow extravasation
of protein inside the retina; however, extravasation is
limited by the external limiting membrane (ELM) due to
its smaller pore size. In severe diabetic maculopathy, there
is dysfunction of the ELM, allowing large-sized protein
molecules to extravasate into the subretinal space, leading
to the formation of subclinical serous macular detachment
(Figures 3c and 3d).
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In recent reports, the incidence of subclinical serous
macular detachment ranges from 2.9% to 15% in eyes with
severe diabetic maculopathy.v-v-":" In a study looking
at serous macular detachment by Kim et al ," focal laser
photocoagulation showed improvement in terms of macular
edema and visual acuity. In a case series by Ozdemir et
al," all cases of serous macular detachment regressed after
intravitreal injection of 4 mg triamcinolone. However, the
effect of intravitreal injection of anti-vascular endothelial
growth factor (anti-VEGF) on serous macular detachment is
not well studied so far. OCT helps to identify this subgroup
of patients where 'apparent' macular edema may seem
to persist despite repeated treatment. OCT can help in
quantitative monitoring of the progress of serous macular
detachment before and after treatment.
9
REVIEW ARTICLE
Changes in the photoreceptor layer
Some patients with DME do not show improvement in
vision despite reduction in retinal thickening after treatment
(either in the form of laser or injection of anti-VEGF or
steroids). This may be related to the foveal photoreceptor
integrity. In particular, the disruption of the inner segment-
outer segment (ISIOS) junction has a reported incidence of
49% to 75%.2830 Greater visual improvement was observed
in those with an intact ISIOS versus those without." In a
recent novel index study, disruption of the ISIOS was shown
to cause a significant decrease of 3.28 dB in retinal point
sensitivity in patients with DME (p < 0.001).37 Other than
ISIOS, other hyper-reftective lines in the outer retina have
been correlated with visual function in DME.28 Otani et aP8
reported a positive relationship between the integrity of
ELM and vision function. The correlation was even stronger
when both ELM and ISIOS were correlated with vision at
the same time. This was in agreement with findings from
a study conducted by Chung et aP8 in which intravitreal
triamcinolone was given for DME. Other than correlation
of vision with ISIOS and ELM, Chung et aP8 also found
that the length of disrupted layers was a crucial factor.
They found that the shorter the length of disruption, the
better the visual outcome, or the more likely the restoration
of disruption. These studies provide evidence to support
the concept that the outer retinal layers could be used as
indicators for visual prognosis, as well as predictors of visual
outcome following treatment. OCT can, therefore, have a
place in the quantitative and qualitative analysis of outer
retinal layers.
Optical coherence tomography-guided
treatment
As a clinical parameter to guide treatment and re-
treatment
In patients with DME, focal laser is currently the standard
treatment of choice according to both the ETDRS and
DRCR.net (Table 1).13 In the ETDRS guidelines, no
OCT parameters were included because OCT was not
available at the time. But in recent studies by DRCR.
net, OCT was used as a means for primary monitoring in
diabetic maculopathy.' In one of their studies, re-treatment
was guided by OCT measurements of macular thickness,
visual acuity and clinical judgment.' OCT measurement is
now recognized as an important clinical parameter in the
clinical management of diabetic maculopathy. Computerized
mapping of the macula by OCT can give sectoral macular
thickness measurements in specific quadrants. The elevation
map is particularly useful for patients to understand the
severity of their macular edema and serial measurements
can also monitor clinical response to treatment and guide re-
treatments (Figures 3e and 31).
Classification by optical coherence tomography
patterns to predict outcome
As mentioned, different types of OCT patterns were
identified in diabetic maculopathy. Kim et aP5 classified
diabetic maculopathy patients into subgroups according to
10
OCT patterns, and correlated with improvement after focal
laser photocoagulation. They have shown that cases with
diffuse retinal thickening had greatest improvement in terms
of reduction in retinal thickening and increase in visual
acuity after focal laser treatment compared with cases with
cystoid macular edema, and VMI abnormalities. Therefore,
identifying OCT patterns in macular edema allows prediction
of outcome after laser treatment.
Early detection of high-risk patients
Despite focal laser therapy, macular edema persists
in a portion of patients. Different treatment strategies
including intravitreal steroid injection, intravitreal anti-
VEGF injections and vitrectomy have been advocated
in these patients.v?' A study by Massin et aP9 found that
vitrectomy was more beneficial in eyes with PDME and
VMI abnormalities than in eyes with PDME without VMI
abnormalities. Now with OCT, we can identify patients with
VMI abnormalities and advocate vitrectomy. Furthermore,
OCT can help to identify any abnormalities in VMI in
proliferative diabetic retinopathy (PDR). In PDR, abnormal
retinal new vessels proliferate on the surface of the retina and
sometimes into the vitreous. It is often difficult to determine
clinically whether the vitreous is still attached to the new
vessels. However, there is an increased risk of progression
and complications such as vitreous hemorrhage in this group
of patients with VMI abnormalities. OCT can play a role
in identifying these high-risk patients, so as to allow more
aggressive treatment plans?'
Limitations
Static imaging
OCT is a static imaging technique; it cannot provide
dynamic information like FFA. Dynamic information such
as vascular perfusion status is essential in the management
of diabetic retinopathy. Evidence of retinal ischemia or
vascular leakage alters management. Hence, in clinical
practice, FFA and OCT complement each other to guide
clinical decisions.
Dependence on media clarity
The quality of OCT is highly dependent on media clarity.
Projection of infrared light from the OCT can be obscured by
any significant opacities along the visual axis. This issue is
especially significant in diabetic patients, as they are known
to have an increased risk of cataract, vitreous hemorrhage
and pre-retinal hemorrhage. All these media opacities may
jeopardize the quality of acquired images.
Lack of reproducibility and repeatability
Ideally, the same plane of interest should be re-imaged at
subsequent follow-ups to allow a fair assessment of the
change in retinal thickness." However, eye movements and
fixation difficulties may affect reproducibility of the scanned
images. To address the concern, the spectral-domain OCTs
have been developed to improve reproducibility due to the
higher scan acquisition speed. Point-to-point correlation
between OCT image and fundus images is now available
HKJOphthalmol ~ Vol.18 No.1
for most spectral-domain aCTs. Good reproducibility was
reported with a Humphrey 2000 aCT prototype system
(Humphrey Instruments, Inc, Dublin [CA], USA), the first
commercially available Zeiss 2000 aCT system (Carl
Zeiss Meditec Inc., Dublin [CA], USA).IO,II,63The Cirrus
Spectral Domain aCT system was reported to have a high
degree of repeatability and reproducibility, which was
more than adequate for clinical purposes. Another study
using the Humphrey aCT system showed retinal thickness
measurements in the macular area to be repeatable and
reproducible.v' These can ensure scanning of the same
location at subsequent visits.65.66 >
Diurnal variation
Several studies have reported issues regarding the time
of scanning due to diurnal variations in retinal thickness
in diabetic patients; the retina is generally thickest in the
morning and is thinner later in the day.67.71However, in
DME, the difference in central sub field thickening between
8 am to 4 pm is too minimal to account for a change in
visual acuity." Hence, the time of scanning is of limited
clinical importance.
Optical coherence tomography in
correlation with other modalities
Optical coherence tomography in correlation with
fundus autofluorescence
Fundus autofluorescence (FAF) is used to assess the capillary
nonperfusion state in patients with DME. FAF visualizes the
distribution of lipofuscin in the retinal pigment epithelium
retinal pigment epithelium (RPE) which is mainly produced
by incomplete degradation of photoreceptor outer segments,
indicative of oxidative damage within the retina." It is
reported that lipofuscin accumulates in microglia in higher
quantities than in the RPE.73 Since microglia are activated
by diabetes, this activation could determine the oxidation of
proteins and lipids that accumulate in the microglia due to
ongoing diabetes. A study by Vujosevic et aF4 revealed that
macular FAF increases in >75% of patients with clinically
significant macular edema and retinal sensitivity decreases
over areas with increased FAF. It also showed that patients
with increased FAF have poorer macular sensitivity. These
findings imply that the sensitivity of the neurosensory retina
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